Michael R Cook, MD
Assistant Professor of Clinical Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Penn Presbyterian Medical Center
51 N 39th St, 1st Floor PAC building
Philadelphia, PA 19104
51 N 39th St, 1st Floor PAC building
Philadelphia, PA 19104
Office: 267-588-2569
Education:
BS (Biology: Vertebrate Physiology; Minor Psychology and Neuroscience)
Pennsylvania State University, 2013.
MD (Medicine)
Lewis Katz School of Medicine at Temple University, 2017.
Permanent linkBS (Biology: Vertebrate Physiology; Minor Psychology and Neuroscience)
Pennsylvania State University, 2013.
MD (Medicine)
Lewis Katz School of Medicine at Temple University, 2017.
Description of Clinical Expertise
Indolent B-cell Lymphoma (Follicular Lymphoma, Marginal Zone Lymphoma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma)Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary Mediastinal B-cell Lymphoma
Selected Publications
Cook, M.R. Williams, L. Kolm, P. Dunleavy, K. : Improved Survival Outcomes for Intensive versus Standard Chemoimmunotherapy in Primary Mediastinal B-cell Lymphoma: A Meta-Analysis of 4068 Patients. Haematologica 109(3), March 2024.Cook, M.R, Shouval, R. Perales, M, et al. : Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL). ASH Annual Conference 2023 Dec 2023 Notes: Oral Presentation.
Cook, M.R. Dorris, SC. Makambi, K. Luo, Y. Munshi, P. Donato, M. Rowley, S. Saad, A. Goy, A. Dunleavy, K. Ali, A. : Toxicity and Efficacy of Chimeric Antigen Receptor (CAR) T-cell Therapy in Primary and Secondary CNS Lymphoma: A Meta-Analysis of 128 Patients. Blood Adv 7(1): 32-39, Jan 2023.
Shah NJ, Cook MR, Wu T, Lev-Ari SL, Blackburn MB, Serzan MT, Alaoui A, Atkins, MB. : Association Between Immune Checkpoint Inhibitors, Corticosteroids, Immunosuppressive Agents and Opportunistic Infections. Journal of the National Comprehensive Cancer Network 20(7), July 2022.
Shah NJ, Cook MR, Wu T, Lev-Ari SL, Blackburn MB, Serzan MT, Alaoui A, Atkins, MB. : The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids J Natl Compr Canc Netw 20(7): 800-807.e1. Jul 2022.
Cook, M.R. Dunleavy, K. : Targeting the Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic strategies. Current Oncology Reports 24: 1121-1131, Apr 2022.
Zhang D, Shah NJ, Cook MR, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins MB, Braithwaite D. : Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers (Basel) 13(23): 6109, Dec 2021.
Cook, M., Dykes, K., White, K., Desale, S., Agrawal, R., Fernandez, S., Huang, X., Cobb, N., Lai, C.: Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19. Clinical Lymphoma, Myeloma & Leukemia Dec 2021.
Cook, M.R. Karp, J.E. Lai, C. : The Spectrum of Genetic Mutations in Myelodysplastic Syndrome: Should We Update Prognostication? EJHaem 3(1): 301-313, Nov 2021.
Cook, M, Dunleavy K. : Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma – Is R-CHOP enough? Blood Adv 5(19): 3873-3875. Oct 2021.